Skip to content
KStart free
AI InfrastructureDefenseQuantumAll studies →

Endocrine Therapy With or Without Abemaciclib (LY2835219) Following Surgery in Participants With Breast Cancer

← catalyst calendar

NCT03155997 · results posted

Sponsored by Eli Lilly and Company (industry) · LLY — their whole pipeline →. With NSABP Foundation Inc.

Phase
Phase 3
Status
Active, not recruiting
Study type
Interventional
Design
Randomized · None · Treatment
Enrollment
5,637actual
Sites
619
Countries
Argentina, Australia, Austria +35

Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →

Source: ClinicalTrials.gov, retrieved 2026-08-19

Dates

each axis at the precision it was filed, with the registry's own basis
DateFiledBasisWhat it is
Start2017-07-12actualWhen the study began enrolling
Primary completion2020-03-16actualThe date the last participant is measured for the primary outcome — the readout window
Study completionMay 2029estimatedThe whole study's end, after follow-up
First posted2017-05-16actualWhen this record first appeared on the registry
Results posted2021-04-09actualWhen the sponsor posted results to the registry
Record updated2026-04-24actualThe sponsor's own last edit to this record — every projection above is as current as this date

What it studies

Condition

  • Breast Cancer

Interventions

  • Drug: Abemaciclib — also filed as LY2835219
  • Drug: Standard Adjuvant Endocrine Therapy

Primary outcome

what the primary-completion date above is the date OF
Invasive Disease Free Survival (IDFS)
measured Baseline to Recurrence or Death from Any Cause (Up to 32 Months)

Posted documents

hosted by the registry — we link, never re-serve
Study Protocolposted 2019-09-18 · 2.6 MB · Prot_000.pdf
Statistical Analysis Planposted 2020-06-05 · 1.3 MB · SAP_001.pdf

Publications

Linked on the registry record. A “linked by the registry” entry is NLM's own automated PubMed match, not a claim by the sponsor that the paper reports this study.

Permalink · LLY's whole pipeline · Catalyst calendar · Every registered study · What changed